Advagene Biopharma Co., Ltd. (6709.TWO)
TWD 19.7
(-0.51%)
TWD 19.7
(-0.51%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -77.69 Million | -109.35 Million | -67.17 Million | -30.88 Million | -35.69 Thousand |
| Net Income | -92.11 Million | -118.37 Million | -92.68 Million | -70.16 Million | -91.61 Thousand |
| Depreciation & Amortization | 12 Million | 11.6 Million | 7.72 Million | 7.88 Million | 6095.00 |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | 12.8 Thousand |
| Change in working capital | 2.49 Million | -2.7 Million | 17.68 Million | 31.65 Million | -8761.00 |
| Other non-cash items | -981 Thousand | -1.23 Million | -1.4 Million | -1.59 Million | 45.78 Thousand |
| Investing Cash Flow | 26.5 Million | 114.28 Million | -81.52 Million | 44.13 Million | 32.74 Thousand |
| Investments in PPE | - | -10.21 Million | -521 Thousand | -627 Thousand | -6.03 Million |
| Acquisitions | - | - | - | - | - |
| Investment purchases | - | -102.4 Million | -79.5 Million | 44.8 Million | - |
| Sales/Maturities of investments | 25 Million | 226.9 Million | - | - | - |
| Other Investing Activities | 1.5 Million | 114.5 Thousand | -1.5 Million | -34 Thousand | 32.78 Thousand |
| Financing Cash Flow | 98.38 Million | -1.26 Million | 41.14 Million | 96.33 Million | 1748.00 |
| Debt repayment | -1929.00 | -1833.00 | -1788.00 | -1782.00 | -1532.00 |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 100.31 Million | 570 Thousand | 42.93 Million | 98.12 Million | - |
| Other Financing Activities | 100.31 Thousand | 570.00 | 42.93 Thousand | 98.12 Thousand | 3280.00 |
| Accounts receivables | - | - | 3991.00 | 951.00 | -4942.00 |
| Accounts payables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other working capital | 1996.00 | -2772.00 | -3662.00 | -2161.00 | -3819.00 |
| Cash at beginning of period | 18 Million | 14.33 Million | 121.89 Million | 12.3 Million | 13.49 Thousand |
| Cash at end of period | 65.19 Million | 18 Million | 14.33 Million | 121.89 Million | 12.3 Thousand |
| Capital Expenditure | - | -10.21 Million | -521 Thousand | -627 Thousand | -6.03 Million |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | 47.18 Million | 3.67 Million | -107.55 Million | 109.59 Million | -1195.00 |
| Free Cash Flow | -77.69 Million | -119.56 Million | -67.69 Million | -31.51 Million | -6.07 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -15.7 Thousand | -15.7 Thousand | -22.74 Thousand | -92.11 Million | -22.74 Thousand | -23.31 Thousand |
| Depreciation & Amortization | 544.50 | 544.50 | 1381.50 | 12 Million | 1381.50 | 1548.50 |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 42.00 | 42.00 | 838.00 | 2.49 Million | 838.00 | 160.00 |
| Other non-cash items | 1676.50 | 1676.50 | 1320.50 | -981 Thousand | 1320.50 | 1958.00 |
| Investing Cash Flow | 227.00 | 227.00 | -4010.00 | 26.5 Million | -4010.00 | 17.26 Thousand |
| Investments in PPE | -16.50 | -16.50 | 240.00 | - | 240.00 | -240.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -39.5 Million | - | - | - | - | - |
| Sales/Maturities of investments | 40 Million | - | - | 25 Million | - | - |
| Other Investing Activities | 243.50 | 243.50 | -4250.00 | 1.5 Million | -4250.00 | 17.5 Thousand |
| Financing Cash Flow | -865.00 | -865.00 | 50.1 Thousand | 98.38 Million | 50.1 Thousand | -911.00 |
| Debt repayment | -806 Thousand | - | - | -1929.00 | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 100.31 Million | - | - |
| Other Financing Activities | -865.00 | -865.00 | 50.1 Thousand | 100.31 Thousand | 50.1 Thousand | -911.00 |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 42.00 | 42.00 | 838.00 | 1996.00 | 838.00 | 160.00 |
| Cash at beginning of period | 65.19 Million | - | -0.50 | 18 Million | -0.50 | - |
| Cash at end of period | -14.07 Thousand | -14.07 Thousand | 26.89 Thousand | 65.19 Million | 26.89 Thousand | -3299.00 |
| Capital Expenditure | -16.50 | -16.50 | 240.00 | - | 240.00 | -240.00 |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -65.2 Million | -14.07 Thousand | 26.89 Thousand | 47.18 Million | 26.89 Thousand | -3299.00 |
| Free Cash Flow | -13.45 Thousand | -13.45 Thousand | -18.96 Thousand | -77.69 Million | -18.96 Thousand | -19.88 Thousand |
BNIX
MC
HMI
OMINFRAL
JXHLY
ELTR